Works matching AU Shoaf, Susan E.

Results: 23

Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats.

Published in:

Journal of Pharmacy & Pharmacology, 2006, v. 58, n. 1, p. 51

By:

Jie Wan;
Lena Ernstgård;
Byoung J. Song;
Susan E. Shoaf

Publication type:

Article

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.

Published in:

Kidney International, 2014, v. 85, n. 4, p. 953, doi. 10.1038/ki.2013.350

By:

Shoaf, Susan E;
Bricmont, Patricia;
Mallikaarjun, Suresh

Publication type:

Article

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Published in:

Kidney International, 2013, v. 84, n. 6, p. 1278, doi. 10.1038/ki.2013.285

By:

Boertien, Wendy E;
Meijer, Esther;
de Jong, Paul E;
Bakker, Stephan J L;
Czerwiec, Frank S;
Struck, Joachim;
Oberdhan, Dorothee;
Shoaf, Susan E;
Krasa, Holly B;
Gansevoort, Ron T

Publication type:

Article

Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia.

Published in:

2003

By:

Elman, Igor;
Lukas, Scott;
Shoaf, Susan E.;
Rott, David;
Adler, Caleb;
Breier, Alan

Publication type:

journal article

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.

Published in:

British Journal of Clinical Pharmacology, 2012, v. 73, n. 4, p. 579, doi. 10.1111/j.1365-2125.2011.04114.x

By:

Shoaf, Susan E.;
Bricmont, Patricia;
Mallikaarjun, Suresh

Publication type:

Article

Does Labeled α-Methyl-L-Tryptophan Image ONLY Blood-Brain Barrier Transport of Tryptophan? (Reply).

Published in:

Journal of Cerebral Blood Flow & Metabolism, 2000, v. 20, n. 10, p. 1511, doi. 10.1097/00004647-200010000-00014

By:

Shoaf, Susan E;
Carson, Richard E;
Herscovitch, Peter;
Eckelman, William C

Publication type:

Article

At‐Home Self‐Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open‐Label Feasibility Trial.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 11, doi. 10.1002/cpdd.1495

By:

Raoufinia, Arash;
Shoaf, Susan E.;
Rothman, Brian;
Ye, Chelsea;
Chung, Chris

Publication type:

Article

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease.

Published in:

Journal of Clinical Pharmacology, 2019, v. 59, n. 5, p. 763, doi. 10.1002/jcph.1370

By:

Lanke, Shankar;
Shoaf, Susan E.

Publication type:

Article

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.

Published in:

Journal of Clinical Pharmacology, 2017, v. 57, n. 7, p. 906, doi. 10.1002/jcph.880

By:

Shoaf, Susan E.;
Chapman, Arlene B.;
Torres, Vicente E.;
Ouyang, John;
Czerwiec, Frank S.

Publication type:

Article

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects.

Published in:

Journal of Clinical Pharmacology, 2011, v. 51, n. 5, p. 761, doi. 10.1177/0091270010376193

By:

Shoaf, Susan E.;
Ohzone, Yoshihiro;
Ninomiya, Shin-ichi;
Furukawa, Masayuki;
Bricmont, Patricia;
Kashiyama, Eiji;
Mallikaarjun, Suresh

Publication type:

Article

Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects.

Published in:

Journal of Clinical Pharmacology, 2007, v. 47, n. 12, p. 1498, doi. 10.1177/0091270007307877

By:

Shoaf, Susan E.;
Zhao Wang;
Bricmont, Patricia;
Mallikaarjun, Suresh

Publication type:

Article

Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults.

Published in:

Journal of Psychopharmacology, 2023, v. 37, n. 2, p. 164, doi. 10.1177/02698811221140008

By:

Matuskey, David;
Gallezot, Jean-Dominique;
Nabulsi, Nabeel;
Henry, Shannan;
Torres, Kristen;
Dias, Mark;
Angarita, Gustavo A;
Huang, Yiyun;
Shoaf, Susan E;
Carson, Richard E;
Mehrotra, Shailly

Publication type:

Article

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects.

Published in:

International Journal of Clinical Pharmacology & Therapeutics, 2012, v. 50, n. 2, p. 150, doi. 10.5414/CP201621

By:

Shoaf, Susan E.;
Bricmont, Patricia;
Mallikaarjun, Suresh

Publication type:

Article

Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.

Published in:

2008

By:

Mallikaarjun S;
Shoaf SE;
Boulton DW;
Bramer SL;
Mallikaarjun, Suresh;
Shoaf, Susan E;
Boulton, David W;
Bramer, Steven L

Publication type:

journal article

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Aripiprazole.

Published in:

Clinical Pharmacokinetics, 2008, v. 47, n. 8, p. 533, doi. 10.2165/00003088-200847080-00003

By:

Mallikaarjun, Suresh;
Shoaf, Susan E.;
Boulton, David W.;
Bramer, Steven L.

Publication type:

Article

Serotonergic influences on life-history outcomes in free-ranging male rhesus macaques.

Published in:

American Journal of Primatology, 2007, v. 69, n. 8, p. 851, doi. 10.1002/ajp.20369

By:

Howell, Sue;
Westergaard, Greg;
Hoos, Beth;
Chavanne, Tara J.;
Shoaf, Susan E.;
Cleveland, Allison;
Snoy, Philip J.;
Suomi, Stephen J.;
Dee Higley, J.

Publication type:

Article

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.

Published in:

Toxicological Sciences, 2017, v. 155, n. 1, p. 61, doi. 10.1093/toxsci/kfw193

By:

Woodhead, Jeffrey L.;
Brock, William J.;
Roth, Sharin E.;
Shoaf, Susan E.;
Brouwer, Kim L. R.;
Church, Rachel;
Grammatopoulos, Tom N.;
Stiles, Linsey;
Siler, Scott Q.;
Howell, Brett A.;
Mosedale, Merrie;
Watkins, Paul B.;
Shoda, Lisl K. M.

Publication type:

Article

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.

Published in:

2019

By:

Schaefer, Franz;
Mekahli, Djalila;
Emma, Francesco;
Gilbert, Rodney D.;
Bockenhauer, Detlef;
Cadnapaphornchai, Melissa A.;
Shi, Lily;
Dandurand, Ann;
Sikes, Kimberly;
Shoaf, Susan E.

Publication type:

journal article

A Thorough QT Study Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization.

Published in:

2024

By:

Shoaf, Susan E.;
Turkoglu, Osman;
Wang, Xiaofeng;
Gordon, Jennifer Repella

Publication type:

Abstract

Population-based meta-analysis of furosemide pharmacokinetics.

Published in:

Biopharmaceutics & Drug Disposition, 2014, v. 35, n. 2, p. 119, doi. 10.1002/bdd.1874

By:

Van Wart, Scott A.;
Shoaf, Susan E.;
Mallikaarjun, Suresh;
Mager, Donald E.

Publication type:

Article

Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.

Published in:

Biopharmaceutics & Drug Disposition, 2013, v. 34, n. 9, p. 527, doi. 10.1002/bdd.1863

By:

Van Wart, Scott A.;
Shoaf, Susan E.;
Mallikaarjun, Suresh;
Mager, Donald E.

Publication type:

Article

Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.

Published in:

Biopharmaceutics & Drug Disposition, 2013, v. 34, n. 6, p. 336, doi. 10.1002/bdd.1849

By:

Van Wart, Scott A.;
Shoaf, Susan E.;
Mallikaarjun, Suresh;
Mager, Donald E.

Publication type:

Article

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.

Published in:

CTS: Clinical & Translational Science, 2021, v. 14, n. 4, p. 1535, doi. 10.1111/cts.13017

By:

Shoaf, Susan E.;
Bricmont, Patricia;
Repella Gordon, Jennifer

Publication type:

Article